Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination

Carmela De Santo, Paolo Serafini, Ilaria Marigo, Luigi Dolcetti, Manlio Bolla, Piero Del Soldato, Cecilia Melani, Cristiana Guiducci, Mario P. Colombo, Manuela Iezzi, Piero Musiani, Paola Zanovello, Vincenzo Bronte

Research output: Contribution to journalArticle

213 Citations (Scopus)

Abstract

Active suppression of tumor-specific T lymphocytes can limit the immune-mediated destruction of cancer cells. Of the various strategies used by tumors to counteract immune attacks, myeloid suppressors recruited by growing cancers are particularly efficient, often resulting in the induction of systemic T lymphocyte dysfunction. We have previously shown that the mechanism by which myeloid cells from tumor-bearing hosts block immune defense strategies involves two enzymes that metabolize L-arginine: arginase and nitric oxide (NO) synthase. NO-releasing aspirin is a classic aspirin molecule covalently linked to a NO donor group. NO aspirin does not possess direct antitumor activity. However, by interfering with the inhibitory enzymatic activities of myeloid cells, orally administered NO aspirin normalized the immune status of tumor-bearing hosts, increased the number and function of tumor-antigen-specific T lymphocytes, and enhanced the preventive and therapeutic effectiveness of the antitumor immunity elicited by cancer vaccination. Because cancer vaccines and NO aspirin are currently being investigated in independent phase I/II clinical trials, these findings offer a rationale to combine these treatments in subjects with advanced neoplastic diseases.

Original languageEnglish
Pages (from-to)4185-4190
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume102
Issue number11
DOIs
StatePublished - Mar 15 2005
Externally publishedYes

Fingerprint

Vaccination
Aspirin
Neoplasms
Nitric Oxide
Myeloid Cells
T-Lymphocytes
Arginase
Phase II Clinical Trials
Clinical Trials, Phase I
Cancer Vaccines
Nitric Oxide Donors
Neoplasm Antigens
nitroaspirin
Nitric Oxide Synthase
Arginine
Immunity
Enzymes
Therapeutics

Keywords

  • Arginase
  • Immunosuppression
  • Immunotherapy
  • Myeloid cells
  • Nitric oxide

ASJC Scopus subject areas

  • Genetics
  • General

Cite this

Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination. / De Santo, Carmela; Serafini, Paolo; Marigo, Ilaria; Dolcetti, Luigi; Bolla, Manlio; Del Soldato, Piero; Melani, Cecilia; Guiducci, Cristiana; Colombo, Mario P.; Iezzi, Manuela; Musiani, Piero; Zanovello, Paola; Bronte, Vincenzo.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 102, No. 11, 15.03.2005, p. 4185-4190.

Research output: Contribution to journalArticle

De Santo, C, Serafini, P, Marigo, I, Dolcetti, L, Bolla, M, Del Soldato, P, Melani, C, Guiducci, C, Colombo, MP, Iezzi, M, Musiani, P, Zanovello, P & Bronte, V 2005, 'Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination', Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 11, pp. 4185-4190. https://doi.org/10.1073/pnas.0409783102
De Santo, Carmela ; Serafini, Paolo ; Marigo, Ilaria ; Dolcetti, Luigi ; Bolla, Manlio ; Del Soldato, Piero ; Melani, Cecilia ; Guiducci, Cristiana ; Colombo, Mario P. ; Iezzi, Manuela ; Musiani, Piero ; Zanovello, Paola ; Bronte, Vincenzo. / Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination. In: Proceedings of the National Academy of Sciences of the United States of America. 2005 ; Vol. 102, No. 11. pp. 4185-4190.
@article{a060f41174984ed090a0bec24d44468b,
title = "Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination",
abstract = "Active suppression of tumor-specific T lymphocytes can limit the immune-mediated destruction of cancer cells. Of the various strategies used by tumors to counteract immune attacks, myeloid suppressors recruited by growing cancers are particularly efficient, often resulting in the induction of systemic T lymphocyte dysfunction. We have previously shown that the mechanism by which myeloid cells from tumor-bearing hosts block immune defense strategies involves two enzymes that metabolize L-arginine: arginase and nitric oxide (NO) synthase. NO-releasing aspirin is a classic aspirin molecule covalently linked to a NO donor group. NO aspirin does not possess direct antitumor activity. However, by interfering with the inhibitory enzymatic activities of myeloid cells, orally administered NO aspirin normalized the immune status of tumor-bearing hosts, increased the number and function of tumor-antigen-specific T lymphocytes, and enhanced the preventive and therapeutic effectiveness of the antitumor immunity elicited by cancer vaccination. Because cancer vaccines and NO aspirin are currently being investigated in independent phase I/II clinical trials, these findings offer a rationale to combine these treatments in subjects with advanced neoplastic diseases.",
keywords = "Arginase, Immunosuppression, Immunotherapy, Myeloid cells, Nitric oxide",
author = "{De Santo}, Carmela and Paolo Serafini and Ilaria Marigo and Luigi Dolcetti and Manlio Bolla and {Del Soldato}, Piero and Cecilia Melani and Cristiana Guiducci and Colombo, {Mario P.} and Manuela Iezzi and Piero Musiani and Paola Zanovello and Vincenzo Bronte",
year = "2005",
month = "3",
day = "15",
doi = "10.1073/pnas.0409783102",
language = "English",
volume = "102",
pages = "4185--4190",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "11",

}

TY - JOUR

T1 - Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination

AU - De Santo, Carmela

AU - Serafini, Paolo

AU - Marigo, Ilaria

AU - Dolcetti, Luigi

AU - Bolla, Manlio

AU - Del Soldato, Piero

AU - Melani, Cecilia

AU - Guiducci, Cristiana

AU - Colombo, Mario P.

AU - Iezzi, Manuela

AU - Musiani, Piero

AU - Zanovello, Paola

AU - Bronte, Vincenzo

PY - 2005/3/15

Y1 - 2005/3/15

N2 - Active suppression of tumor-specific T lymphocytes can limit the immune-mediated destruction of cancer cells. Of the various strategies used by tumors to counteract immune attacks, myeloid suppressors recruited by growing cancers are particularly efficient, often resulting in the induction of systemic T lymphocyte dysfunction. We have previously shown that the mechanism by which myeloid cells from tumor-bearing hosts block immune defense strategies involves two enzymes that metabolize L-arginine: arginase and nitric oxide (NO) synthase. NO-releasing aspirin is a classic aspirin molecule covalently linked to a NO donor group. NO aspirin does not possess direct antitumor activity. However, by interfering with the inhibitory enzymatic activities of myeloid cells, orally administered NO aspirin normalized the immune status of tumor-bearing hosts, increased the number and function of tumor-antigen-specific T lymphocytes, and enhanced the preventive and therapeutic effectiveness of the antitumor immunity elicited by cancer vaccination. Because cancer vaccines and NO aspirin are currently being investigated in independent phase I/II clinical trials, these findings offer a rationale to combine these treatments in subjects with advanced neoplastic diseases.

AB - Active suppression of tumor-specific T lymphocytes can limit the immune-mediated destruction of cancer cells. Of the various strategies used by tumors to counteract immune attacks, myeloid suppressors recruited by growing cancers are particularly efficient, often resulting in the induction of systemic T lymphocyte dysfunction. We have previously shown that the mechanism by which myeloid cells from tumor-bearing hosts block immune defense strategies involves two enzymes that metabolize L-arginine: arginase and nitric oxide (NO) synthase. NO-releasing aspirin is a classic aspirin molecule covalently linked to a NO donor group. NO aspirin does not possess direct antitumor activity. However, by interfering with the inhibitory enzymatic activities of myeloid cells, orally administered NO aspirin normalized the immune status of tumor-bearing hosts, increased the number and function of tumor-antigen-specific T lymphocytes, and enhanced the preventive and therapeutic effectiveness of the antitumor immunity elicited by cancer vaccination. Because cancer vaccines and NO aspirin are currently being investigated in independent phase I/II clinical trials, these findings offer a rationale to combine these treatments in subjects with advanced neoplastic diseases.

KW - Arginase

KW - Immunosuppression

KW - Immunotherapy

KW - Myeloid cells

KW - Nitric oxide

UR - http://www.scopus.com/inward/record.url?scp=20144375187&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20144375187&partnerID=8YFLogxK

U2 - 10.1073/pnas.0409783102

DO - 10.1073/pnas.0409783102

M3 - Article

C2 - 15753302

AN - SCOPUS:20144375187

VL - 102

SP - 4185

EP - 4190

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 11

ER -